Public release date: 23-Feb-2011
Contact: Vanessa Pavinato
European Society for Medical Oncology
European Multidisciplinary Conference in Thoracic Oncology -- press program
The following studies will be presented in the Press Program of the second European Multidisciplinary Conference in Thoracic Oncology, a multipartner initiative for physicians of all medical disciplines dealing with lung cancer and other thoracic malignancies.
The full text of the embargoed press releases/abstracts can be requested to the EMCTO Press Office at email@example.com. When the embargo lifts, the texts will be available in the ESMO Online Newsroom.
- Quick, easy test identifies aggressive type of lung cancer in never-smokers (embargo: 25 February 2011, 8:00 CET)
Inexpensive and rapid test can effectively identify sub-group of never-smoking lung cancer patients whose tumors express molecule associated with increased risk of disease progression or recurrence.
Author: Ping Yang, US
- Oncogene AEG-1 strongly predicts response to erlotinib treatment in EGFR-mutant lung cancer (embargo: 25 February 2011, 8:00 CET)
Researchers identified a gene whose expression level strongly predicts how well and how long certain lung cancer patients will respond to treatment with erlotinib.
Author: Rafael Rosell, Spain
- Bone drug zoledronic acid may help prevent spread of early lung cancer (embargo: 25 February 2011, 8:00 CET)
Drug currently used to help treat bone metastases in patients with lung cancer could also be useful at an earlier state of treatment to prevent cancer from spreading.
Author: Michela Quirino, italy
- Radio-guided surgery, a safe and simple way to remove potentially cancerous nodules in the lung (embargo: 26 February 2011, 8:00 CET)
Using tiny spheres of radioactive liquid to guide surgeons as they remove potentially cancerous material in the lungs is safe and more effective than other techniques.
Author: Luca Bertolaccini, Italy
- Phase III trial: erlotinib as effective as chemo, with fewer side-effects, in patients whose disease progressed after first-line treatment (embargo: 26 February 2011, 8:00 CET)
Targeted cancer drug erlotinib has comparable efficacy to chemotherapy and is better tolerated in hard-to-treat cases where a patient's cancer has progressed quickly after treatment with first-line therapy.
Author: Tudor Ciuleanu, Romania
The full conference program is available at http://www.esmo.org/events/lung-2011-emcto/program.html
Please contact the EMCTO Press Office at firstname.lastname@example.org to schedule your remote interviews or register for the event.
All sessions are open to journalists and registration is free to bona fide journalists on presentation of a valid press card and/or of a letter of assignment.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.